Nykode Therapeutics : ABGSC Life Science Summit 30-31 May 2023 – presentation
June 07, 2023 at 06:30 am
Share
ABGSC Life Science Summit
Stockholm
May 30
Forward-looking statement
This announcement and any materials distributed in connection with this presentation may contain certain forward- looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate.
A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.
Nykode Therapeutics | ABGSC Life Science Summit
2
Global leader in APC-targeted immunotherapy technology
NYKODE THERAPEUTICS (NYKD-OL, MKT CAP ~$700M)
Proprietary immunotherapies targeting antigens to Antigen-Presenting Cell (APC) and generating strong CD8 killer T cell responses correlated with clinical responses in solid tumors
Modular, versatile platform
Easily incorporate new antigens and adapt to new diseases across oncology, infectious diseases and autoimmunity
Rapidly advancing wholly owned lead asset, VB10.16, immunotherapy for HPV16+ cancers
Final data from phase 2 VB-C-02- unprecedented long lasting survival benefit in advanced cervical cancer
Potentially registrational study in advanced cervical cancer to initiate 2023
Dose escalation study with KEYTRUDA®1 in head and neck cancer to initiate 1H2023
Strategic partnerships to advance clinical programs and commercialize assets worldwide2
Well-capitalized with a cash position of $186m at March 31, 2023
Note: KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA
Note: Genentech has an exclusive license to VB10.NEO. Collaboration and license to 5 programs with Regeneron. Collaboration and license with Adaptive Biotechnologies on SARS-CoV-2 T cell vaccine. Roche supplies atezolizumab; . Merck (MSD) supplies pembrolizumab
Nykode Therapeutics | ABGSC Life Science Summit
3
Nykode executive management
Experienced and international management team
MICHAEL ENGSIG
AGNETE FREDRIKSEN
MIKKEL W. PEDERSEN
KLAUS EDVARDSEN
HARALD GURVIN
Chief Executive Officer
Chief Business Officer &
Chief Scientific Officer
Chief Development Officer
Chief Financial Officer
Co-founder
Nykode Therapeutics | ABGSC Life Science Summit
4
Rich and diversified pipeline
Asset
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Rights
Oncology
VB10.16
HPV16+ cervical cancer
VB10.16
HPV16+ head and neck cancer
Off-the-shelf
Regeneron
Undisclosed
programs
Internal
Undisclosed
Melanoma, lung, bladder, renal,
VB10.NEO
head and neck cancer; locally
Individualized
advanced and metastatic tumors
VB10.NEO
Locally advanced and
metastatic tumors
Infectious Disease
1
2
3
4
4
Regeneron
Undisclosed
programs
Internal
Undisclosed
Autoimmune
3
Internal
Undisclosed
1. Wholly-owned by Nykode. Potentially registrational. Roche supplies atezolizumab; 2. Wholly-owned by Nykode. Merck (MSD) supplies pembrolizumab; 3. Collaboration with Regeneron; 4. Genentech has an exclusive license to VB10.NEO.
Nykode Therapeutics | ABGSC Life Science Summit
5
Attachments
Original Link
Original Document
Permalink
Disclaimer
Nykode Therapeutics AS published this content on 07 June 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 June 2023 05:29:01 UTC.
Nykode Therapeutics ASA is a Norway-based clinical-stage biopharmaceutical platform company dedicated to the discovery and development of vaccines and immunotherapies for cancer and infectious diseases. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The Company develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeuticsâ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The Company also has two universal COVID-19 vaccine candidates in development.